Navigation Links
Kidney cancer subtype study finds low recurrence and cancer death rates
Date:3/29/2012

Patients with papillary renal cell carcinoma, the second most common kidney cancer subtype, face a low risk of tumour recurrence and cancer-related death after surgery. Those are the key findings of a multi-centre study of nearly 600 patients published in the April issue of the urology journal BJUI.

"Because papillary renal cell carcinoma (pRCC) only affects ten to 15% of kidney cancer patients, the small number of patients enrolled in individual studies makes it hard to draw meaningful conclusions about how the disease will progress" says lead author Dr Vincenzo Ficarra, associate professor of urology at the University of Padua, Italy.

"Bringing together data on 577 patients from 16 academic centres across Italy has enabled us to study this subtype in more detail than a single-centre study would allow."

The patients with pRCC were identified from 5,463 patients with suspected renal cell carcinoma at the centres between 1995 and 2007. Follow-up ranged from 22 to 72 months and the median was just over 39 months.

Key findings of the study, which forms part of a larger research project promoted by LUNA, the clinical research office of the Italian Society of Urology, include:

  • Patients averaged 62.4 years of age and 77% were male. The majority had presented with incidental symptoms (64%) and the size of the pathological tumours ranged from 3cm to 7cm, with a median size of 4.3cm.

  • Most patients (62%) had radical nephrectomy surgery, where the entire kidney and its collecting system is removed, along with the adrenal gland, the fat tissue around the kidney and the associated lymph glands.

  • At follow-up, 81% of the patients were alive and disease free. A further 14% had experienced disease progression, 11% had died from the disease and 5% had died from causes other than cancer.

  • The overall average recurrence-free survival rates after surgery were 85.5% and 73.1% respecti
    '/>"/>

Contact: Annette Whibley
annette.wizard@gmail.com
Wiley-Blackwell
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
2. New drug for kidney transplant recipients effective in humans
3. Drug for advanced kidney cancer shrinks tumors prior to surgery
4. Obesity -- mild or severe -- raises kidney stone risk
5. VARI findings may help patients with deadly kidney cancer
6. Kidneys From Older Donors Suitable for Seniors
7. Comparison shows robot-assisted option offers advantages for kidney surgery
8. Walk KidneyWise Los Angeles to Help Launch KidneyWise with Fundraising Walk in Santa Monica
9. Board Certified Renal Specialist, Nina Kolbe, Publishes Second Edition of Kidney Health Gourmet: A Diet Guide and Kidney Friendly Recipes for People Not on Dialysis
10. American Kidney Fund Raises Awareness, Honors Kidney Heroes during National Kidney Month
11. National Kidney Month 2010: Stories of Hope About the Prevention and Maintenance of Kidney Disease from The Kidney TRUST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Dennis Thompson HealthDay Reporter ... combination of therapy and antidepressants appears to best help ... reports. Four out of five people suffering from ... recovery when treated with cognitive therapy plus antidepressant medication, ... didn,t work much better than drugs alone in helping ...
(Date:8/21/2014)... 2014 Seattle, WA chiropractors Dr. ... Eastlake Chiropractic and Massage Center have recently welcomed ... Rina Lang, LMP and Mike Larios, LMP have ... massage techniques, and have developed their expertise working in ... particularly important in a clinical environment where massage is ...
(Date:8/21/2014)... August 21, 2014 The results of ... in The Journal of the American Medical Association (JAMA) ... cancers and reduces unnecessary recalls. Memorial Healthcare System was ... study. , “This study confirms what we already know ... cancers we want to find and, at the same ...
(Date:8/21/2014)... The second bellwether trial involving ... has begun in Massachusetts state court. The device ... Law Group LLP, a national personal injury law ... stemming from the implantation of mesh products, provides ... injuries suffered at http://www.wehelpwomen.com/transvaginal-mesh/ . , Maria ...
(Date:8/21/2014)... The Swedish-American Life Science Summit, (SALSS) ... on the Future of Medicine and the challenges ... , With the mission to turn new sciences ... business and science. "Over the years SALSS has ... diverse community with representatives challenging the boundaries of ...
Breaking Medicine News(10 mins):Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 3Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 2Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 3Health News:Dr. Mary Hayes: Study Shows 3D Mammography Finds More Invasive Cancers While Reducing Unnecessary Recalls 2Health News:Transvaginal Mesh Lawsuit News: Second Boston Scientific Mesh Bellwether Trial Begins, The Rottenstein Law Group LLP Reports 2Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2
... , , , ... DST Health Solutions, a leading provider of software and services ... certification, a designation demonstrating its commitment to quality product development. ... Registrar, an independent auditing firm, for meeting the guidelines set ...
... LEBANON, Tenn., July 28 Health Connect Partners, Inc. ( ... the title sponsor of its 2009 Fall Hospital Pharmacy Conference. ... up to 200 directors of pharmacy from some of the largest ... sessions led by healthcare industry experts, the Hospital Pharmacy Conference will ...
... COLORADO SPRINGS, Colo., July 28 Now that summer is in ... across the county. , , With millions enjoying their ... for home pool and hot tub safety is urgent. , , ... home pool and hot tub owners to make safety their priority by following ...
... , WILTON, Conn., July 28, ... Friday, July 24 and Saturday, July 25 in Chicago, Eucerin was ... incidental sun exposure and give them a glimpse into their skin,s ... year marked Eucerin,s first appearance at the annual BlogHer Conference, connecting ...
... , CHICAGO, July 28 When at the pool ... the harmful rays of the sun. But do we remember to apply sunscreen to ... on the feet from unprotected sun exposure, and overlook applying sunscreen to the area. ... of the foot is prevalent and can even be fatal if not caught early. ...
... Mylan Inc. (Nasdaq: MYL ) today reported that in ... proactively and as a courtesy had contacted the U.S. Food and ... a recent news article. As a result, the FDA visited the ... the baseless accusations in the article were unfounded. The FDA noted ...
Cached Medicine News:Health News:DST Health Solutions Achieves ISO 9001:2008 Certification 2Health News:Cardinal Health Announced as Title Sponsor of the Health Connect Partners' 2009 Fall Hospital Pharmacy Conference 2Health News:Seven Tips for Safer Home Swimming Pools and Hot Tubs 2Health News:Eucerin Provides BlogHer Attendees With a Glimpse Into Their Skin's Future With Proprietary 'Time Machine' Aging Simulator 2Health News:Sunscreen on Your Feet? Doctors Urge Sunscreen Use and Exams to Prevent Skin Cancer on Feet 2Health News:Mylan Reports That the FDA Determined That All Accusations Were Unfounded 2
(Date:8/21/2014)... SAN JOSE, Calif. , Aug. 21, 2014 /PRNewswire/ ... a medical device company that pioneered the use of ... surgical (MIS) device indicated for fusion of the sacroiliac ... ) published an update to its Lumbar Fusion ... MIS SI joint fusion procedure.  The policy states that ...
(Date:8/21/2014)... , Aug. 21, 2014   Auxilium ... a specialty biopharmaceutical company, today announced positive results ... collagenase clostridium histolyticum (or CCH) for the treatment ... cellulite. In the Phase 2a trial, all three ... high (0.84mg)) showed an improvement in the appearance ...
(Date:8/20/2014)... , Aug. 20, 2014  The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Indiana blocked the sale of ...
Breaking Medicine Technology:SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ... candidate, has been granted orphan drug designation from the ... of pediatric Clostridium difficile infection (CDI).  This ... covers all formulations of fidaxomicin used to treat ...
... 2011 ULURU Inc. (NYSE Amex: ULU), ... a portfolio of wound management and oral care products, today ... 5,000,000 shares of its common stock at a price per ... an institutional investor, resulting in gross proceeds of approximately $500,000. ...
Cached Medicine Technology:Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection 2Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection 3Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection 4ULURU Inc. to Raise $500,000 in Registered Direct Offering 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: